Vol 28, No 6 (2021)
Research Letter
Published online: 2021-10-27

open access

Page views 6530
Article views/downloads 602
Get Citation

Connect on Social Media

Connect on Social Media

Successful treatment of severe COVID-19 pneumonia with tocilizumab: A series of three cases

Joanna Chochoł-Labun1, Renata Wachnicka-Truty1, Małgorzata Sinica-Latecka1, Katarzyna Sikorska2, Marek Koziński1
Pubmed: 34708860
Cardiol J 2021;28(6):979-982.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Abani O, Abbas A, Abbas F, et al. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285): 1637–1645.
  2. Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021; 384(16): 1491–1502.
  3. Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021; 384(1): 20–30.
  4. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020; 383(24): 2333–2344.
  5. Hermine O, Mariette X, Tharaux PL, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021; 181(1): 32–40.
  6. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021; 384(16): 1503–1516.
  7. Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021; 181(1): 24–31.
  8. Veiga VC, Prats JA, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021; 372: n84.
  9. Akinosoglou K, Velissaris D, Ziazias D, et al. Remdesivir and tocilizumab: Mix or match. J Med Virol. 2021; 93(1): 56–58.
  10. Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021; 3: CD013881.